thebench.bio #1 Ecosystem for the Bio-Tech Industry

Biotech industry news

Where our news comes from

Every story is pulled from a source on this list. We add sources by hand and never crawl the open web, an open crawler is how a curated feed turns into a content farm.

Industry trade press

Newsrooms that cover drug development as a beat, daily.

  • AC
    Applied Clinical Trials

    Clinical operations as a beat of its own: monitoring, data management, sites and sponsors. Nothing else on this list covers the work most clinical staff actually do.

  • BioPharma Dive

    Breaking news with the context attached: funding, trials and deals, written for people who work in the industry.

  • BI
    BioPharm International

    CMC, formulation and analytics: the daily subject of the roles nobody else writes about.

  • BioSpace

    Industry news with an unusually strong careers desk, so it covers hiring and layoffs as a subject rather than as an aside.

  • BioWorld

    Biopharma, regulatory, clinical and financing in one wire, with unusually complete deal coverage.

  • Clinical Trials Arena

    Trial operations and the CRO industry, which is a large share of European hiring and thinly covered elsewhere.

  • Drug Delivery Business

    Delivery platforms, devices and the companies building them, which is where a lot of the formulation hiring sits.

  • Drug Discovery and Development

    Preclinical pipelines and the tooling around them, including where machine learning has actually landed.

  • Fierce Biotech

    Broad daily coverage across biotech, with strong reporting on layoffs and site closures.

  • Fierce Pharma

    Big pharma: approvals, commercialisation and manufacturing, which is where most of the jobs are.

  • GEN

    Omics, gene editing and bioprocessing: the techniques our bench and process listings ask for by name.

  • Inside Precision Medicine

    Diagnostics, companion tests and the clinical end of omics. A sister title to GEN, so the duplicate rule in News::IngestFeedService is what keeps one story to one card.

  • MedCity News

    Funding, startups and IPOs at the healthcare end, narrowed to the biopharma desk.

  • Medical Design and Outsourcing

    Device engineering and the contract manufacturers behind it, written for the engineers rather than about them.

  • MedTech Dive

    Devices and diagnostics. Adjacent to biotech and a real part of the same labour market.

  • PC
    Pharmaceutical Commerce

    Market access, commercialisation and supply chain, which is the half of the industry the science press skips.

  • PE
    Pharmaceutical Executive

    The commercial side: launch, pricing and market access. Nothing else here covers the half of the industry that decides whether a drug reaches anybody.

  • Pharmaceutical Processing World

    Plants, fill-finish and capacity announcements. A new line somewhere is a hiring plan somewhere, usually a quarter ahead of the adverts.

  • Pharmaceutical Technology

    Manufacturing and development, including the automation work that is changing what a process role looks like.

  • P
    Pharmafile

    British pharma business, short and daily. Thin on analysis and useful for the deals the larger titles skip.

  • P
    pharmaphorum

    Commercial and medical affairs coverage, a part of the industry the others under-serve.

  • PharmaVoice

    Leadership and strategy. Useful for the moves and reorganisations that precede hiring.

  • STAT Biotech

    Original reporting on biotech, trials, the FDA and policy. Slower than the wires, and usually the version that holds up.

  • TechCrunch Biotech and Health

    Techbio and synthetic biology from the venture side, which reaches companies before the trade press does.

Scientific journals

Peer-reviewed publishers and their news desks.

  • B
    BioTechniques

    Methods and techniques rather than business: assays, metabolomics, instrumentation. The bench half of what the trade press reports as deals.

  • CS
    Cell Systems

    Systems and computational biology, in press rather than published, so it arrives before the journal issue does.

  • C&EN Pharmaceuticals

    Medicinal chemistry and manufacturing from the chemistry side, which is where a lot of our listings actually sit.

  • FL
    Front Line Genomics

    British genomics coverage with a sequencing and computational bias, which is the angle the general trade press reaches last.

  • IT
    In the Pipeline

    Derek Lowe reading the drug discovery literature in public. One person, and the most useful judgement in the field.

  • NB
    Nature Biomedical Engineering

    Devices, delivery and diagnostics as engineering. The academic end of what MedTech Dive reports as business.

  • Nature Biotechnology

    Peer-reviewed methods and platform advances, ahead of the trade press by months.

  • NM
    Nature Medicine

    Where a trial result becomes evidence rather than a press release, months before the trade press treats it as settled.

  • NR
    Nature Reviews Bioengineering

    Reviews rather than primary papers, which is the right grain for a reader deciding whether a field is worth retraining into.

  • Nature Reviews Drug Discovery

    Where modality and approval trends are argued out before the trade press reports them as facts.

  • PB
    PLOS Biology

    Open access, so every story on this row links to something a reader can actually read. The only publisher here of which that is true.

  • PF
    Practical Fragments

    Dan Erlanson and Teddy Zartler on fragment-based drug discovery, since 2008 and still weekly. Narrow on purpose: it is read by the people who do this for a living.

  • SN
    Science News

    The AAAS newsroom rather than the journal: research policy, funding and misconduct, which move careers more than any single paper does.

  • V
    Virological

    Where genomic epidemiologists post an outbreak analysis before a preprint exists. It is a Discourse forum, so the feed carries thread activity rather than finished articles: the highest signal here and the least tidy.

  • WD
    What do you mean heterogeneity?

    Valentine Svensson on the statistics of single-cell RNA sequencing. Dense, quantitative and the reason this row is under journals rather than under commentary.

Regulators and agencies

Primary sources: agencies publishing their own decisions.

  • Bio.News

    Policy and biosecurity from the industry association. Read as a position rather than as reporting.

  • EMA Press

    Primary source. Approvals and guidance straight from the agency, not summarised.

  • E
    EUCOPE

    The European trade body for small and mid-sized health technology companies, which is exactly the employer this board serves. Read as a position, like Bio.News, and it is the only source here covering EU policy from that side.

  • FL
    FDA Law Blog

    Hyman, Phelps and McNamara on orphan drugs, biosimilars and exclusivity, in more detail than anybody else bothers with.

  • FDA Press Announcements

    Primary source for US decisions, which drive hiring in regulatory affairs everywhere.

  • GO
    GCBR Organization Updates

    A monthly account of what the pandemic preparedness and biosecurity organisations are actually doing, which is where a surprising number of computational roles sit.

  • MHRA

    The third regulator beside the FDA and the EMA. Since Brexit a British approval is its own event, and this is the agency publishing it rather than somebody reporting it.

  • PD
    Patent Docs

    Biotech and pharma IP. A patent decision reshapes a pipeline, and therefore a hiring plan, years ahead.

  • S
    SecureBio

    Technically grounded essays on AI and biological risk. Here with Bio.News because biosecurity is policy, and like Bio.News it is a position rather than reporting.

Regional and cluster press

Local coverage of a specific biotech cluster or market.

  • E
    EMBL

    Europe's flagship molecular biology laboratory, heavily computational across EMBL-EBI, imaging and structural biology, and a major employer in six countries. Its own Workday link is the lab hiring for itself, which is the EMA and FDA precedent rather than a jobs board.

  • European Biotechnology

    Continental biotech business in English, covering the German, Swiss and Nordic companies the English-language trade press reaches late.

  • Labiotech

    The best single source on the European biotech scene, and on the clusters we hire into.

Financial and markets

Markets coverage where it bears on hiring and funding.

  • BioCentury

    Strategy, partnering and investment. Funding rounds are the leading indicator of hiring.

  • LifeSciVC

    Atlas Venture writing about company building and biotech economics from inside the cap table.

  • TL
    The Labs Report

    Flagship Pioneering writing about the companies it builds. Carried for the same reason as LifeSciVC and read the same way: this is a shareholder describing its own portfolio.

Engineering biology and software

Where computation, AI and engineering meet the bench, written by people doing it.

  • AB
    AIxBio Briefing

    Quarterly, with a five item archive. The smallest row on this list and carried because its subject is the intersection this category exists for.

  • AP
    Asimov Press

    Long-form essays on engineered biology, editorially independent of the company whose name it carries. The best writing in this category and the one to read if you only read one.

  • B
    Biocene

    Shelby Newsad on how science gets funded and how biological data gets priced, which is the commercial question under every techbio story.

  • BS
    Bio Signal

    A few posts a year on scientific autonomy, spatial biology and therapeutic strategy. Quiet enough that it is here for the pieces rather than the feed.

  • BC
    Biotech Currents

    Independent commentary, carried as a second opinion against the trade press above rather than as a source of facts.

  • BO
    Bits of DNA

    Lior Pachter on single-cell methods, quantification and research integrity. Confrontational and usually right, which is why it is worth the low volume.

  • BB
    Briefly Bio

    Lab automation and agents in the lab, written seriously rather than as vendor copy. The only source found on this subject that is not a supplier's blog, and it posts rarely.

  • Decoding Bio

    Computational biology and machine learning applied to drug discovery, written by people building it rather than reporting on it.

  • Ground Truths

    Eric Topol on AI and medicine: long, evidence-led and consistently ahead of the trade press on what the models can actually do.

  • MG
    Matt Gamber

    An independent weekly read on biotech with a computational slant, written by one person with no employer to please.

  • M
    MetaphysicalCells

    Weekly European coverage of AI in drug discovery, which is the cadence Decoding Bio and Owl Posting do not have.

  • MA
    Molecules and Empires

    Monthly long-form on how a scientific breakthrough reshapes an industry. A small archive and good writing.

  • OO
    Omics! Omics!

    Keith Robison on sequencing technology, taking instrument chemistry and vendor claims apart in a way no trade publication attempts. Several posts a month.

  • Owl Posting

    Essays on where AI in biology has and has not worked. One person and a post a month, so it is here for the quality and not the cadence.

  • PE
    Paired Ends

    Stephen Turner rounding up genomics methods, tools and papers weekly. One of the few individual feeds in this field with a real cadence.

  • SC
    Sarah Constantin

    Quantitative essays on biotech and metascience by a mathematician who reads the primary literature. Independent of every interest this industry has.

  • SB
    Scaling Biotech

    Jesse Johnson on how software, automation and data actually get adopted inside a biotech organisation, which is a different question from whether the methods work. Weekly.

  • TC
    The Century of Biology

    Elliot Hershberg on the companies and ideas at the frontier of biology. Infrequent, which is stated here rather than discovered later: the newest post when this row was added was three months old.

  • TN
    The Niche

    Paul Knoepfler on stem cells and cell therapy, including the unproven-clinic trade nobody else names. A working scientist writing under his own name about an industry that would rather he did not.

  • TW
    This Week in Cheminformatics

    A weekly digest of cheminformatics papers, preprints and tool releases. A feeder for the primary literature we deliberately do not carry.

  • WB
    Weekly Bioinformatics

    One genomics result or method per post, unpacked properly. Roughly monthly despite the name.

  • WT
    Weekly Tech+Bio

    A weekly round-up of where machine learning is actually landing in drug discovery, with the deals attached. The cadence Decoding Bio and Owl Posting do not have.

Agricultural and food biotech

Plant and food biotechnology: a different industry with the same science under it.

  • AgriBusiness Global

    The trade from a European regulatory angle, which is the part of agricultural biotech that moves fastest and matters most here.

  • CropLife

    Crop protection and biologicals, including the product approvals that decide what gets developed next.

  • ES
    European Seed

    Plant breeding and seed policy in Europe, including gene editing law. High volume, so it is the one to stop reading first if the column gets crowded.

  • Global Ag Tech Initiative

    Where agriculture meets sensing, data and automation. The same engineering that turns up in bioprocess roles, one industry along.

Bioprocessing and contract manufacturing

How a biologic is actually made, at scale and under contract.

  • BI
    BioProcess International

    The trade paper for biomanufacturing: process development, scale-up, single-use and facility build-outs. The feed at /feed is dead and /rss.xml is the live one.

  • CP
    Contract Pharma

    Outsourced development and manufacturing, which is the half of the industry that hires without ever owning a molecule. Roughly weekly, so it is here for the subject rather than the cadence.

Research software and methods

The people who build and maintain the tools, writing about them.

  • AS
    Arcadia Science

    A for-profit research organisation publishing its work directly as web-native pubs, negative results included. The highest volume row on this list at 125 items, so it is the first to watch if the column floods.

  • B
    BLOPIG

    The Oxford Protein Informatics Group writing weekly about antibody modelling and protein machine learning. It posts its own group vacancies in a blog category, which is a lab advertising its own openings rather than a jobs board.

  • CZ
    Chan Zuckerberg Biohub

    AI for biology from the Biohub network: protein modelling, cell imaging, the virtual cell. An institutional voice, but it describes results rather than ambitions.

  • C
    ChEMBL-og

    The EMBL-EBI team behind ChEMBL on releases, schema changes and chemical data curation. European, public, and the canonical source for anybody building on it.

  • CW
    Corin Wagen

    Short essays on simulation, computational chemistry and building a scientific software company from somebody doing both.

  • C
    Cradle

    Protein design machine learning from a Delft and Zurich company, with real method write-ups. **The feed address is not Cradle's**: their site exposes none, so this is generated by a third party and will break one day with nobody to tell us.

  • DT
    Dave Tang

    Fifteen years of worked bioinformatics walkthroughs. Reference material rather than news, and carried because a reader who follows one of these links learns something.

  • DA
    Diamond Age Data Science

    A bioinformatics consultancy writing honestly about what works in production rather than what demos well. A company blog that earns its place, which most do not.

  • HL
    Heng Li

    The author of BWA, minimap2 and samtools on algorithms and data formats. Quarterly at best, and here for the same reason Owl Posting is: nobody else can write these posts.

  • IF
    Institute for Protein Design

    The centre of gravity of computational protein design, and the institute whose spinouts hire across this field. The Baker Lab's own feed fails TLS certificate validation, so this is the one address worth reading.

  • IL
    Is life worth living?

    A working computational chemist posting short runnable RDKit and PyTorch notebooks, several times a month. No press releases, ever.

  • J
    JEFworks

    The Jean Fan lab at Johns Hopkins on spatial transcriptomics, plus unusually candid posts on running a computational group.

  • LB
    Latch Bio

    The strongest engineering blog of any company in this field: agent benchmarks for biological analysis, continuous benchmarking, biosecurity engineering. Almost no marketing, which is rare enough to be the reason it is here.

  • MI
    Mac in Chem

    Chris Swain on scientific computing for chemists: scripts, tooling and language-model experiments. The apex host, because www.macinchem.org redirects.

  • MD
    Molecular Design

    Peter Kenny arguing, at length and in public, that the field's methods do not measure what they claim to. Adversarial by design and the counterweight to every other row in this category.

  • N
    Nextstrain

    Real-time pathogen phylogenetics tooling. Software and biology in the same post, which is the whole reason this category exists.

  • N
    nf-core

    The Nextflow pipeline community: releases, maintainer notes and workflow engineering practice. As close as this field gets to a trade paper for bioinformatics engineers.

  • OT
    Open Targets

    Target identification as data science, from the EMBL-EBI, GSK, Sanofi and Genentech consortium. Genetics to drug, with the methodology published.

  • PA
    Pistoia Alliance

    The pre-competitive consortium for life science R&D data standards: FAIR data, lab data architecture, preclinical submission. Software inside pharma, and covered essentially nowhere else.

  • PC
    Practical Cheminformatics

    Pat Walters benchmarking machine learning for small-molecule discovery rather than announcing it. The feed carries whole posts and runs to 4.3 MB, which is inside Core::FetchUrlService::MAX_BYTES and the largest thing on this list.

  • RB
    RDKit Blog

    Greg Landrum on the toolkit most of cheminformatics is built on. Reproducible posts on fingerprints, conformers and performance, from the person who wrote it.

  • RW
    Ryan Wick

    Long-read assembly benchmarking from the author of Unicycler and Trycycler. Methodical and test-driven, which is rarer in this field than it should be.

  • S
    scverse

    Scanpy, AnnData and the single-cell Python ecosystem: releases and design decisions. Quiet, and its newest post was three months old when this row was added.

Industry headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.

Industry BioCentury

Innovation Radar: New clues to targeting Alzheimer’s microglia

BIOCENTURY | DISCOVERY & TRANSLATIONINNOVATION RADAR: NEW CLUES TO TARGETING ALZHEIMER’S MICROGLIAGenetic findings and oral TREM2 data advance microglial approaches, while tissue and mouse studies offer clues to treatment timing

12d ago

Industry GEN

Gene That Preserves Bone Stem Cell Supply Throughout Life Identified

Researchers found that the HOXA10 gene preserves bone stem cell supply throughout life, and say the discovery advances understanding of stem cell biology and could indicate potential therapeutic approaches to improve bone healing and regeneration in aging and disease. The post Ge…

13d ago

Industry Inside Precision Medicine

Ultrasound Implant Could Allow Real-Time Monitoring of Spinal Cord Injury

A miniature ultrasound device can be temporarily implanted at the site of a spinal cord injury to monitor patients in real time and support recovery. The post Ultrasound Implant Could Allow Real-Time Monitoring of Spinal Cord Injury appeared first on Inside Precision Medicine.

13d ago
PE

Industry P Pharmaceutical Executive

Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie

How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lal…

13d ago

Industry Inside Precision Medicine

SuperAgers Offer Window on Alzheimer’s Risk

A machine-learning framework can judge where a person's brain function lies between SuperAgers and a diagnosis of Alzheimer’s disease. The post SuperAgers Offer Window on Alzheimer’s Risk appeared first on Inside Precision Medicine.

13d ago

Industry GEN

HIV-Blocking Antibody Shows Promise, but Resistant Strains Break Through

A new study finds that the VRC01 antibody initially protects against HIV infection, but resistant strains can cause breakthrough infections as antibody levels decline, highlighting the need for multiple antibodies. The post HIV-Blocking Antibody Shows Promise, but Resistant Strai…

13d ago

Industry Inside Precision Medicine

New Standard-of-Care for KRAS G12C-Mutated Advanced NSCLC

The next-generation KRAS G12C inhibitor divarasib improved progression-free and overall survival compared with sotorasib or adagrasib in previously treated advanced NSCLC. The post New Standard-of-Care for <i>KRAS</i> G12C-Mutated Advanced NSCLC appeared first on Insi…

13d ago

Industry MedCity News

Servier Stumbles in Muscle Disease as Drug From $1.5B Deal Fails Pivotal Test

Servier’s sevasemten came from the acquisition of the muscular dystrophy assets of Edgewise Therapeutics. While the small molecule had met the goal of a Phase 2 test in Becker muscular dystrophy, Servier said new results in a pivotal cohort do not show statistically significant b…

13d ago

Industry GEN

Building Custom DNA without Bacterial Constraints

Moving high-fidelity DNA assembly from the production queue to the lab bench and the science can start sooner. The post Building Custom DNA without Bacterial Constraints appeared first on GEN - Genetic Engineering and Biotechnology News.

13d ago

Industry BioCentury

Lilly extends GLP-1 lead — except in orals

BIOCENTURY | DATA BYTELILLY EXTENDS GLP-1 LEAD — EXCEPT IN ORALSTirzepatide tops $16B in quarterly sales, putting annual revenue on pace to exceed $60B

13d ago
AC

Industry A Applied Clinical Trials

De-Risking FIH: Integrated Strategies for Rapid Proof-of-Concept (Sept 2026)

First-in-human studies are often where promising programs encounter delays, uncertainty, and increased risk. This whitepaper examines strategies to de-risk early clinical development through integrated trial design, CMC planning, and streamlined execution, helping sponsors genera…

13d ago

Industry GEN

Standardized Apheresis Processes Would Help Cell Therapy Sector

Variation in collection practices, or apheresis, and handling procedures is a source of cell therapy starting material variability and a major headache for manufacturers, suggesting a degree of standardization would help the industry. The post Standardized Apheresis Processes Wou…

13d ago

Industry GEN

Small Bioprocess Monitoring Hits the Goldilocks Zone

A viable-cell-density-on-a-chip monitor offers hope for more fully functional, PAT-compliant in-line monitoring for small bioprocesses, filling a current instrumentation gap. The catch? It’s still in early development. The post Small Bioprocess Monitoring Hits the Goldilocks Zone…

13d ago

Industry GEN

Suspended Vials Help Optimize Continuous Freeze-Drying

Researchers have developed a process with suspended vials accompanied by a digital twin for optimized continuous and autonomous freeze-drying. It offers more uniform and better-quality products, and higher yields. The post Suspended Vials Help Optimize Continuous Freeze-Drying ap…

13d ago

Industry GEN

Greener Biomanufacturing Starts Beyond the Bioreactor

A new modeling study finds that buildings, not bioreactors, dominate energy consumption in antibody manufacturing. Continuous processing and smarter facility design could reduce emissions, but water and disposable materials complicate sustainability decisions for manufacturers wo…

13d ago

Industry Drug Delivery Business

MiniMed names new CMO ahead of planned retirement

MiniMed (Nasdaq: MMED) has named a new chief medical officer, as its current leader plans to retire at the end of next year. Dr. David Segal takes over for Dr. Robert Vigersky, who will now move into an emeritus position after holding the title of CMO since 2019 — back when the n…

13d ago

Industry B BioTechniques

Closing time for IL-39?

Researchers seem to have demonstrated that the much-debated interleukin, IL-39, can’t be secreted by human cells, but it could serve as a valuable engineered tool for immunology and drug design. A recent research effort from a team at the Technical University of Munich (Germany),…

13d ago

Industry MedTech Dive

3 takeaways from TCT 2026

Edwards’ TAVR device in moderate aortic stenosis drew applause from meeting attendees, while Medtronic’s renal denervation and Abbott’s left atrial appendage closure devices also produced positive study results.

13d ago

Industry E EMBL

Understanding the rules of brain cancer

AI and single-cell omics technologies are helping us uncover the rules that determine how cells in glioblastoma – a type of incurable brain cancer – acquire different fates, enabling researchers to experimentally change them.

13d ago

Industry P Pharmaceutical Commerce

Pharma Pulse: CVS Health to Break in Two, Bayer Weighs MFN

In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.

13d ago

Industry P Pharmafile

Five Facts about medicinal cannabis and chronic disease

1 Chronic pain is generally defined as pain that persists or recurs for more than three months. It can arise from an underlying condition or exist as a condition in its own right. In England, 26% of adults reported chronic pain in the 2024 Health Survey for England, with 13% expe…

13d ago

Industry Inside Precision Medicine

Ryan Beal: Getting Under Cancer’s Skin

In this Behind the Breakthroughs, Dyve Biosciences' transdermal delivery approach targets acidic microenvironments that promote cancer cell growth and inflammation to treat immunologic and oncologic diseases. The post Ryan Beal: Getting Under Cancer’s Skin appeared first on Insid…

13d ago